Leeds joins partners in £170m European drug development project
Chemists at the University of Leeds will join a £170 million pan-European project, bringing together university researchers and pharmaceutical companies to develop the next generation of drugs.
The European Lead Factory, a novel platform for innovative drug
discovery, will bring together an international consortium of 30
partners. This is the first partnership of its kind, supported by the
Innovative Medicines Initiative (IMI), the worlds largest
public-private partnership in health.
The project will create unprecedented opportunities to jointly discover new medicines, through access to a molecule library collection based at BioCity Scotland.
Traditionally, pharmaceutical companies have had vast libraries of compounds held in safeguarded corporate chemical collections which can be screened in the hunt for potential medicines. Access to these compound libraries is usually highly restricted.
The seven participating pharmaceutical companies in the European Lead Factory will collectively contribute a total of 300,000 compounds to a new library. An additional 200,000 compounds will be developed jointly by researchers from the Universities of Leeds and Nottingham in the UK and by small and medium enterprises (SMEs).
This will lead to the establishment of the Joint European Compound Collection consisting of half a million compounds that will be accessible to all project partners and to any European organisations that submit promising new targets for drug discovery selected through competitive calls.
Professor Adam Nelson, from the School of Chemistry, will coordinate the review and selection of innovative chemistry proposals from across Europe that will enhance the Joint European Compound Collection. The team in the School of Chemistry, led by Professor Nelson, Professor Steve Marsden and Dr Richard Foster, will contribute to this effort.
It is very exciting that innovative new chemistry from academia will be brought to bear in a wide range of drug discovery programmes. This platform of innovation will be complemented by the pharmaceutical industrys ability to develop marketed drugs, and will result in a new model for drug development in Europe, said Professor Adam Nelson.
You can read more about this project on the University's external website.